200 million eczema sufferers. A leading drug that fails more than half of them. A cancer-causing alternative that still projects $5 billion in sales. And a tiny 60-person San Francisco biotech that may have cracked the code — with a Nobel Prize-validated mechanism the market is somehow pricing at near-zero. This week, Krzysztof goes full deep-dive on Nectar Therapeutics ($NKTR), while Luke — self-confessed biotech skeptic — has the options chain open and his wallet ready.📊 Why the world's most common skin disease has NO good cure yet — and why that $50B market opportunity is hiding in plain sight💊 The cancer-warning drug that still projects $3–5B in revenue: what that tells you about how desperate patients really are🎓 Res-peg explained without the jargon: the Nobel Prize-backed immune reset mechanism that makes $NKTR different from every other AD drug on the market💀 The 33% single-day crash that Monkey calls 'borderline irrational' — and why buying that dip may have been one of the most logical trades of the year🎯 Bull, base, and bear: a $240–$320 price target vs. today's ~$82 — and the position sizing rules that keep this from becoming a gamble🧠 Why the market can't walk and chew gum: how $NKTR's alopecia data confusion is creating a 'free call option' that most investors are completely missing🌐 The imminent April catalyst that could reprice this stock overnight — and why Monkey says a negative surprise would be the real shockSources:Adam May (biotech investor): https://x.com/A_May_MDSegments:00:00:00 The Disease Affecting 200 Million People With No Real Cure00:05:00 What Is Atopic Dermatitis (Eczema) — And Why It's a $50B Market00:10:00 Why the Best Drug on the Market Only Works for Half of Patients00:15:00 The Cancer-Warning Drug Still Projecting $5B in Sales00:20:00 $NKTR's Res-Peg: The Nobel Prize-Backed Mechanism Explained00:27:00 The Phase 2 Data That Sent $NKTR From $6 to $8000:33:00 The Alopecia Trial Disaster — And Why Monkey Says the Market Overreacted00:43:00 Valuation Deep Dive: Is $NKTR Worth 4x From Here?00:48:00 Upcoming Catalysts: What to Watch in April 2025 and Beyond00:54:00 Position Sizing in Biotech — How Much Is Too Much?01:01:00 Options Strategy for $NKTR: Calls vs. Shares vs. Selling Puts

**********

If you want to see our furry faces, this podcast is also available on YouTube at ⁠youtube.com/@WallStreetWildlife?sub_confirmation=1⁠

**********

SUPPORT THE SHOW AND BECOME A PATREON:

wallstreetwildlife.com

**********

⁠⁠x.com/7LukeHallard

⁠x.com/7FlyingPlatypus

**********

Fiscal.AI is the Complete Stock Research Platform for fundamental investors. With its beautiful design and institutional-quality data, Fiscal AI is incredibly powerful and easy to use.

Get 15% off any premium plan with:

fiscal.ai/wildlife

**********

Monkey’s “Zen, Nietzsche, How to Live” Substack:

firephilosophy.substack.com

**********

To use the same portfolio tracking tool as Luke, check-out:

portseido.com/?fpr=lukehallard

**********

Disclosure: Wall Street Wildlife hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation

**********

Fed up with the stock market giving you a hard time?

- Invest like seasoned pros with over 40 years in the game

- Discover the world's leading companies

- Sharpen your best investing practices and ditch the worst

- Learn how to start investing

- Essential investing principles to boost your returns

Keywords:

$NKTR, Nectar Therapeutics, atopic dermatitis, eczema investing, biotech stock 2025, res-peg, alopecia treatment, biotech options strategy, small cap biotech, phase 2 clinical trial, biotech position sizing, $KYMR, Dupixent competitor, JAK inhibitors, T regulatory cells, biotech catalyst, Wall Street Wildlife, undervalued biotech, options implied volatility, Kelly Criterion biotech, free call option, clinical trial design, immune system investing, rezpegaldesleukin